Related Experiment Video
Updated: Jun 28, 2025
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors
Giuseppe Corrias1, Eleonora Lai2, Pina Ziranu2
1Department of Radiology, University of Cagliari, 09042 Cagliari, Italy.
Abstract:
Colorectal cancer (CRC) is a leading tumor worldwide. In CRC, the angiogenic pathway plays a crucial role in cancer development and the process of metastasis. Thus, anti-angiogenic drugs represent a milestone for metastatic CRC (mCRC) treatment and lead to significant improvement of clinical outcomes. Nevertheless, not all patients respond to treatment and some develop resistance. Therefore, the identification of predictive factors able to predict response to angiogenesis pathway blockade is required in order to identify the best candidates to receive these agents. Unfortunately, no predictive biomarkers have been prospectively validated to date. Over the years, research has focused on biologic factors such as genetic polymorphisms, circulating biomarkers, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and microRNA. Moreover, research efforts have evaluated the potential correlation of molecular biomarkers with imaging techniques used for tumor assessment as well as the application of imaging tools in clinical practice. In addition to functional imaging, radiomics, a relatively newer technique, shows real promise in the setting of correlating molecular medicine to radiological phenotypes.
Insights
Predicting response to anti-angiogenic drugs in metastatic colorectal cancer (mCRC) is crucial. Identifying predictive biomarkers for angiogenesis pathway blockade is needed, as current methods lack prospective validation.
Area of Science:
- Oncology
- Molecular Biology
- Radiology
Background:
- Colorectal cancer (CRC) is a major global health concern.
- The angiogenic pathway is critical for CRC development and metastasis.
- Anti-angiogenic drugs have improved outcomes for metastatic CRC (mCRC), but response varies.
Purpose of the Study:
- To identify predictive factors for response to angiogenesis pathway blockade in mCRC.
- To address the lack of prospectively validated predictive biomarkers for anti-angiogenic therapy.
Main Methods:
- Investigated various biological factors including genetic polymorphisms, circulating biomarkers, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and microRNA.
- Evaluated the correlation between molecular biomarkers and imaging techniques for tumor assessment.
- Explored the application of functional imaging and radiomics in correlating molecular medicine with radiological phenotypes.
Main Results:
- Research has explored numerous biological markers for predicting treatment response.
- Correlation studies have linked molecular biomarkers with imaging findings.
- Radiomics shows promise in bridging molecular characteristics with radiological phenotypes.
Conclusions:
- Predictive biomarkers are essential for optimizing anti-angiogenic therapy in mCRC.
- A combination of molecular and imaging approaches, including radiomics, may offer future solutions.
- Further validation of predictive markers is necessary for clinical application.
More Related Videos
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
